Cite
HARVARD Citation
Grellety, T. et al. (2016). PRognostic factor of Early Death In phase II Trials or the end of 'sufficient life expectancy' as an inclusion criterion? (PREDIT model). BMC cancer. 16 (1), pp. 1-8. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Grellety, T. et al. (2016). PRognostic factor of Early Death In phase II Trials or the end of 'sufficient life expectancy' as an inclusion criterion? (PREDIT model). BMC cancer. 16 (1), pp. 1-8. [Online].